Abstract

Lithium carbonate has a narrow therapeutic range capable of producing various adverse effects; despite this fact, it is used as first-line therapy in patients with bipolar disorder (BD) thanks to its high effectiveness. Among its adverse events are several conditions at the endocrine level, such as hypothyroidism, hyperthyroidism, hypercalcemia, hyperparathyroidism, and nephrogenic diabetes insipidus. The adherence to current guidelines for monitoring those events is low. The objective of this review is to provide insight into the pathophysiological mechanisms of the endocrine effects of lithium and give recommendations based on the current literature for the monitoring and treatment of these conditions. © 2024 Sociedad Medica de Santiago. All rights reserved.